- Market Capitalization, $K 3,198,967
- Shares Outstanding, K 30,890
- Annual Sales, $ 12,730 K
- Annual Income, $ -295,160 K
- 60-Month Beta 2.28
- Price/Sales 248.51
- Price/Cash Flow N/A
- Price/Book 4.55
|Period||Period Low||Period High||Performance|
| || |
-18.90 (-16.00%)since 10/18/19
| || |
-51.64 (-34.23%)since 08/20/19
| || |
-22.00 (-18.15%)since 11/20/18
New Records and New Milestones
Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.
GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day
Investors can still hold on to CVS Health (CVS) stock, thanks to its solid prospects.
CVS Health's (CVS) Health Care Benefits segment develops Medicare program with Aetna.
Bull of the Day: GW Pharmaceuticals (GWPH)
Syneos Health (SYNH) aims to optimize patient engagement and trial success by partnering with AiCure.
Investors continue to be optimistic about NuVasive's (NUVA) stellar performance.
Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.
The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.
The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.
Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
The market is in highly oversold territory. Beware of a trend reversal.
|Gw Pharma ADR|
|Advisorshares Pure Cannabis ETF|
|Pharmaceutical Vaneck ETF|
|Nasdaq Biotechnology Ishares ETF|
|Bldrs Europe Select ADR Index Fund Invesco|
|Bldrs Developed Markets 100 ADR Index Fund Inves|